Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide.

Drug Des Devel Ther · 2016 · PMC4751980 · PMID 26917951

Europe PMC DOI

hedged sentences

0.0546

closest p · 1.1× alpha

0.0546

boldest claim

The sentences

a trend toward significanceP =0.0546so close (0.05 < p ≤ 0.1)

The analysis also showed a trend toward significance ( P =0.0546) in dyskinetic patients who had not changed their l -dopa dose during the trial.

also in 3,729 other papers

borderline significantno p-value reported

There was a borderline significant improvement in ADL for 100 mg/d measured by UPDRS part II and European quality of life. 18 Clinical studies in advanced PD Study 016 19 was a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group trial with four phases: a 10-day screening period, a 4-week l -dopa stabilization period, a 24-week treatment period, and an optional 1-week taper period.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.